Bellevue Group AG Sells 84,994 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Bellevue Group AG trimmed its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 65.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 44,833 shares of the medical research company’s stock after selling 84,994 shares during the period. Bellevue Group AG’s holdings in IQVIA were worth $8,810,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of IQV. Bank of America Corp DE raised its holdings in shares of IQVIA by 30.3% in the 4th quarter. Bank of America Corp DE now owns 1,255,535 shares of the medical research company’s stock worth $246,725,000 after buying an additional 291,816 shares in the last quarter. BLI Banque de Luxembourg Investments acquired a new position in IQVIA during the fourth quarter worth $16,939,000. BNP Paribas lifted its holdings in shares of IQVIA by 52.7% during the fourth quarter. BNP Paribas now owns 6,608 shares of the medical research company’s stock valued at $1,303,000 after acquiring an additional 2,280 shares during the period. BNP Paribas Financial Markets grew its holdings in shares of IQVIA by 66.5% in the 4th quarter. BNP Paribas Financial Markets now owns 476,442 shares of the medical research company’s stock worth $93,626,000 after purchasing an additional 190,360 shares during the last quarter. Finally, Ameriprise Financial Inc. increased its position in shares of IQVIA by 1.5% during the 4th quarter. Ameriprise Financial Inc. now owns 971,133 shares of the medical research company’s stock worth $190,838,000 after purchasing an additional 14,004 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Trading Up 1.5 %

IQV opened at $153.42 on Friday. The firm’s fifty day moving average is $167.52 and its two-hundred day moving average is $191.06. The firm has a market cap of $27.05 billion, a PE ratio of 20.46, a price-to-earnings-growth ratio of 1.99 and a beta of 1.46. IQVIA Holdings Inc. has a twelve month low of $135.97 and a twelve month high of $252.88. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84.

IQVIA (NYSE:IQV) last posted its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Equities research analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on IQV. Citigroup dropped their price objective on shares of IQVIA from $225.00 to $210.00 and set a “neutral” rating for the company in a report on Tuesday, March 4th. Truist Financial dropped their price target on IQVIA from $263.00 to $216.00 and set a “buy” rating for the company in a report on Thursday, April 10th. Stifel Nicolaus decreased their target price on IQVIA from $273.00 to $261.00 and set a “buy” rating on the stock in a report on Friday, February 7th. StockNews.com cut IQVIA from a “buy” rating to a “hold” rating in a report on Wednesday, March 12th. Finally, HSBC lowered shares of IQVIA from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $260.00 to $160.00 in a report on Friday, April 25th. Eight analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, IQVIA has an average rating of “Moderate Buy” and a consensus price target of $237.62.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.